Intermitent Hypoxia and Its Pathophysiology Consequences in the Sleep Apnea-Hypopnea Syndrome.
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Alberto Alonso Fernandez
- Trial code
- NCT04444778
- Record updated
- 7 October 2026
- Original description
Clinical trial on the effect of continuous positive pressure (CPAP). Objectives: 1) To assess the total or partial recovery of oxidative and inflammatory damage after recovering IH. 2) To check whether the results obtained in vitro on the recovery of the damage according to the form of manifestation of IH are validated in SAHS patients. 3) To determine if CPAP reduces nighttime blood pressure and arterial stiffness depending on whether or not patients have a non-dipping pattern of blood pressure and depending on the degree of correction of IH. 4) To clarify whether residual nocturnal hypoxemia influences the recovery of oxidative and inflammatory damage in patients. 5) To determine nasal and intestinal microbioma and the effect of CPAP treatmentRead full original descriptionShow less
Intermitent Hypoxia and Its Pathophysiology Consequences in the Sleep Apnea-Hypopnea Syndrome. Basic, Clinical and Therapeutically Study.
Clinical trial on the effect of continuous positive pressure (CPAP). Objectives: 1) To assess the total or partial recovery of oxidative and inflammatory damage after recovering IH. 2) To check whether the results obtained in vitro on the recovery of the damage according to the form of manifestation of IH are validated in SAHS patients. 3) To determine if CPAP reduces nighttime blood pressure and arterial stiffness depending on whether or not patients have a non-dipping pattern of blood pressure and depending on the degree of correction of IH. 4) To clarify whether residual nocturnal hypoxemia influences the recovery of oxidative and inflammatory damage in patients. 5) To determine nasal and intestinal microbioma and the effect of CPAP treatment
Inclusion: Cases: patients with AHI > 30; Controls: subjects with AHI < 5 and Epworth >10.
Exclusion: Concomitant treatment with antihypertensives, statins, antidiabetics, beta-blockers or systemics corticosteroids; Participation in another clinical trial thirty days prior to randomization; Arterial Hypertension; Mellitus Diabetes; Cerebrovascular disease; Ischemic heart disease; Cardiac arrhythmia; Chronic cardiovascular diseases; Epworth>18; BMI<40Kg/M2; Daytime Oxygen saturation>95%; Risk professions (professional drivers); Pretreatment with CPAP.